---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-085976"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:43:17.770347+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

## Summary
- TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).
- Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.
- Safety profile consistent with prior Tyvaso studies; no new safety signals observed.
- Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026.

## SEC filing metadata
- accession: 0001104659-25-085976
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/0001104659-25-085976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/tm2524831d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-085976
- JSON: https://secwatch.observer/filing/0001104659-25-085976.json
- Plain text: https://secwatch.observer/filing/0001104659-25-085976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.